OraSure Technologies, Inc. (OSUR)

Over the past six months, OraSure Technologies' stock experienced several notable events. In Q3 2025, management described 2025 as a transition year and projected a return to growth in 2026. The 52-week low stock price for OSUR was $2.08 on November 21, 2025. The company held earnings conference calls for Q4 2025 and Q1 2026. OraSure reported Q1 2026 net revenues of $27.9 million, a 7% decrease year-over-year, and missed consensus EPS estimates by $0.08. The company returned $20 million of capital to shareholders through share repurchases. Management expects mid-year FDA clearances and commercial launches for its CT/NG rapid molecular OTC self-test and the Colli-Pee at-home urine collection device, with revenue ramps anticipated in the second half of 2026.

OraSure Technologies' products and services experience demand seasonality, which can lead to lower gross margins in certain quarters, such as Q4. The company has also faced disruptions in ordering patterns from a key consumer genetics customer, impacting its Sample Management Solutions revenue.

OraSure Technologies, Inc. specializes in diagnostic products and sample management solutions, emphasizing rapid, non-invasive testing and decentralized healthcare. The company operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry, with core businesses in Diagnostics and Sample Management Solutions. Major products include rapid diagnostic tests, drug testing systems, molecular sample management solutions, microbiome products, in development tests for CT/NG, other diagnostic products, and sickle cell disease testing.

OraSure Technologies is headquartered in Bethlehem, Pennsylvania, USA, with its largest employee base and manufacturing facility there. It has expanded globally through acquisitions, including Ottawa, Ontario, Canada (DNA Genotek team), Morrisville, North Carolina, USA (BioMedomics team), and Newton, Massachusetts, USA, and Cambridge/Oxford, UK (Sherlock Biosciences teams). OraSure's products are sold globally to various entities, including clinical laboratories, hospitals, and direct consumers.

OraSure Technologies' brand reputation has been shaped by its strategic transformation and commitment to improving healthcare access through innovative diagnostic solutions. The company's mission to decentralize diagnostics and empower individuals with actionable health insights contributes positively to its brand image. The company has continued to highlight its product development and strategic acquisitions, such as BioMedomics, to expand its diagnostics portfolio, reinforcing its reputation as an innovator in the diagnostics space.

OraSure Technologies' ownership is dominated by institutional investors, including BlackRock, Inc., The Vanguard Group, Private Management Group Inc, Neuberger Berman Group LLC, Dimensional Fund Advisors Lp, Altai Capital Management, L.P., Renaissance Technologies Llc, Acadian Asset Management Llc and Cannell Capital Llc. Insider holdings are also notable.